FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100052454> ?p ?o ?g. }

• W2100052454 endingPage "251" @default.
• W2100052454 startingPage "237" @default.
• W2100052454 abstract "Abstract5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer. Research has focused on the biomodulation of 5-FU in order to attempt to improve the cytotoxity and therapeutic effectiveness of this drug in the treatment of advanced colorectal cancer. Modulation of 5-FU by methotrexate (MTX), trimetrexate(TMTX), interferon-α (IFN-α), leucovorin (LV), or N-(phosphonacetyl)-L-asparte acid (PALA) has produced higher response rates than those observed with 5-FU alone. Methotrexate may improve the durability of response to or survival with 5-FU, but with inferior results compared with those in trials of 5-FU and leucovorin. Trimetrexate produces a number of responses, and further phase III trials are in progress to confirm the results of promising phase II trials with this drug. IFN-a has shown therapeutic efficiency when combined with 5-FU alone or with 5-FU and leucovorin, but latest studies with these combinations have shown increased toxicity. Initial single-institution phase I trials with 5-FU and PALA reported promising responses, but the latter responses with PALA were not substantiated in randomized multicenter trials. Leucovorin enhances the cytotoxic activity of 5-FU in vitro and in vivo, and several clinical trials have shown improved response rates and possible trends in improved survival when such therapy is compared with the use of 5-FU as a single-agent. More recent randomized trials have focused their attention on determining the optimal dose and schedule with this combination for producing a better clinical response with minimal toxicity. Schedules using infusional 5-FU appear to be the most active regimens when 5-FU is used as a single agent, as demonstrated by recent randomized trials. The Southwest Oncology Group (SWOG) and the Eastern Cooperative Oncology Group (ECOG) have performed separate randomized trials and have shown that the optimal regimens employ infusional 5-FU as a single agent, and that these are the least toxic regimens, perhaps more effective, and associated with a better quality of life.Future studies will focus on infusional regimens involving either short-term, high-dose protracted or long-term, low-dose protracted infusion of 5-FU, since these regimens have shown the most favorable toxicity spectrum and produced the longest survival times. Future research will also focus on the evaluation of various methods of delivery of 5-FU, including oral administration of the drug in combination with compounds that can modify its catabolism." @default.
• W2100052454 created "2016-06-24" @default.
• W2100052454 creator A5008907100 @default.
• W2100052454 creator A5039901253 @default.
• W2100052454 creator A5043198546 @default.
• W2100052454 creator A5047162703 @default.
• W2100052454 date "1998-01-01" @default.
• W2100052454 modified "2023-09-24" @default.
• W2100052454 title "Biomodulation of Fluorouracil in Colorectal Cancer" @default.
• W2100052454 cites W1535441861 @default.
• W2100052454 cites W1548032098 @default.
• W2100052454 cites W1812173233 @default.
• W2100052454 cites W1837458449 @default.
• W2100052454 cites W1844072307 @default.
• W2100052454 cites W1847455118 @default.
• W2100052454 cites W1863898801 @default.
• W2100052454 cites W1869910714 @default.
• W2100052454 cites W1885154202 @default.
• W2100052454 cites W1902766545 @default.
• W2100052454 cites W1916504364 @default.
• W2100052454 cites W1964296661 @default.
• W2100052454 cites W1964768968 @default.
• W2100052454 cites W1967980267 @default.
• W2100052454 cites W1969387370 @default.
• W2100052454 cites W1971325806 @default.
• W2100052454 cites W1972465013 @default.
• W2100052454 cites W1979110171 @default.
• W2100052454 cites W1980253503 @default.
• W2100052454 cites W1996640078 @default.
• W2100052454 cites W1999471341 @default.
• W2100052454 cites W2000972831 @default.
• W2100052454 cites W2003204054 @default.
• W2100052454 cites W2004322406 @default.
• W2100052454 cites W2005946785 @default.
• W2100052454 cites W2009729947 @default.
• W2100052454 cites W2009794857 @default.
• W2100052454 cites W2011569241 @default.
• W2100052454 cites W2011646339 @default.
• W2100052454 cites W2014203514 @default.
• W2100052454 cites W2018152179 @default.
• W2100052454 cites W2021591179 @default.
• W2100052454 cites W2030818307 @default.
• W2100052454 cites W2030955710 @default.
• W2100052454 cites W2033798598 @default.
• W2100052454 cites W2037099262 @default.
• W2100052454 cites W2055626187 @default.
• W2100052454 cites W2055983050 @default.
• W2100052454 cites W2062717712 @default.
• W2100052454 cites W2064803636 @default.
• W2100052454 cites W2064920797 @default.
• W2100052454 cites W2068049913 @default.
• W2100052454 cites W2068510939 @default.
• W2100052454 cites W2083338379 @default.
• W2100052454 cites W2088728307 @default.
• W2100052454 cites W2088915390 @default.
• W2100052454 cites W2090237280 @default.
• W2100052454 cites W2093657716 @default.
• W2100052454 cites W2111189177 @default.
• W2100052454 cites W2131702638 @default.
• W2100052454 cites W2132039541 @default.
• W2100052454 cites W2139040913 @default.
• W2100052454 cites W2175524623 @default.
• W2100052454 cites W2179172424 @default.
• W2100052454 cites W2227311140 @default.
• W2100052454 cites W2227373247 @default.
• W2100052454 cites W2234894755 @default.
• W2100052454 cites W2253033732 @default.
• W2100052454 cites W2255330917 @default.
• W2100052454 cites W2258295221 @default.
• W2100052454 cites W2260298745 @default.
• W2100052454 cites W2269247374 @default.
• W2100052454 cites W2269468903 @default.
• W2100052454 cites W2271306081 @default.
• W2100052454 cites W2272332804 @default.
• W2100052454 cites W2274948752 @default.
• W2100052454 cites W2297807805 @default.
• W2100052454 cites W2320893138 @default.
• W2100052454 cites W2460562859 @default.
• W2100052454 cites W2463396699 @default.
• W2100052454 cites W2602544133 @default.
• W2100052454 cites W4231300735 @default.
• W2100052454 cites W4239498835 @default.
• W2100052454 cites W4243932715 @default.
• W2100052454 cites W4244302123 @default.
• W2100052454 cites W2067117255 @default.
• W2100052454 doi "https://doi.org/10.3109/07357909809039773" @default.
• W2100052454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9589033" @default.
• W2100052454 hasPublicationYear "1998" @default.
• W2100052454 type Work @default.
• W2100052454 sameAs 2100052454 @default.
• W2100052454 citedByCount "33" @default.
• W2100052454 countsByYear W21000524542012 @default.
• W2100052454 countsByYear W21000524542014 @default.
• W2100052454 countsByYear W21000524542015 @default.
• W2100052454 countsByYear W21000524542016 @default.
• W2100052454 countsByYear W21000524542017 @default.
• W2100052454 countsByYear W21000524542018 @default.
• W2100052454 countsByYear W21000524542019 @default.

• next